Loading...
Although docetaxel-based chemotherapy confers a modest survival benefit in patients who have metastatic castrate-refractory prostate cancer (CRPC; JW Oncol Hematol Feb 5 2008), no subsequent treatments have proven useful once docetaxel is stopped because of toxicity or disease progression. Promising earlier findings in CRPC patients who received satraplatin — a novel oral platinum compound — led researchers to compare this agent with placebo in a manufacturer-funded phase III trial.
In all, 950 patients who had metastatic CRPC that progressed despite previous chemotherapy were randomized to oral satraplatin (80 mg/m2) or placebo daily for the first 5 days of a 35-day cycle; both groups received prednisone (5 mg twice daily). Progression-free…